Costing vascular surgery: A review of current reporting practice  by Shackley, Phil et al.
To the two certainties in life, death and taxes, can be
added a third—the need to make choices. This need
arises from the simple fact that resources are finite.
Implied demands on resources greatly exceed the capac-
ity of resources to meet those demands. Therefore,
choices have to be made about which activities should
and should not be undertaken. This applies as much to
health care as to any other sector. In choosing to use
resources in one beneficial activity, an alternative benefi-
cial use of those resources is implicitly given up. The
benefit forgone from not deploying resources in their
next best alternative use defines the economist’s notion
of the cost (or opportunity cost) of those resources. If we
are concerned with maximizing benefits from limited
resources, then only those activities for which benefits
exceed cost should be undertaken.
To assess whether benefits exceed costs, we must
use some form of economic evaluation. Economic
evaluation can take many forms, but underlying each
is the same basic principle that both the costs and
the benefits of alternative uses of resources are mea-
sured and valued.1 The various techniques of eco-
nomic evaluation are now accepted tools for the
appraisal of health care programs, and worldwide
there is a growing volume of economic evaluations
in the health care field.2-6 An increasing number of
economic evaluations are being performed and are
appearing in the literature, and that is a good thing.
As the literature expands, however, it becomes
increasingly important for decision makers to be able
to separate the “good” studies from the “bad.” To
facilitate this quality assessment process, a number of
critical appraisal guidelines have been produced.7-12
Most notable among them are those produced by
Drummond et al7 (see Appendix I).
Although there is undoubtedly a need for such
guidelines, the successful application of the critical
appraisal criteria embodied within the guidelines is
crucially dependent on the extent to which the study
methods and results are reported. If the level of
reporting is such that it is not possible to apply all of
the critical appraisal criteria, then any judgment
regarding the quality of the study is undermined. For
example, an economic study may have been performed
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well and be methodologically sound, but if the level of
reporting is such that third parties cannot assess the
validity of the work, then the usefulness and potential
impact of the study are significantly diminished. The
extent to which this occurs is a function of the infor-
mation omitted. Other things being equal, the more
inadequate the reporting, the less one is able to judge
the quality of a study and, consequently, the less con-
fidence one has in the study’s results and recommen-
dations. In effect, adequate reporting of economic
studies can be regarded as a prerequisite (or necessary
condition) for an assessment of a study’s quality.
The importance of establishing reporting
guidelines for economic studies has recently been
acknowledged,13,14 and such guidelines have
started to appear.15-17
In view of the importance of reporting standards to
the overall assessment of the quality of economic stud-
ies, the aim of this article is to investigate the extent of
reporting in the area of peripheral vascular surgery. To
facilitate this aim, a systematic review of the journal lit-
erature between 1986 and the first half of 1997 was
undertaken to identify relevant economic studies.
Strictly speaking, an economic evaluation considers
both costs and benefits; however, in practice, many
studies do not tackle the more complex assessment of
benefit but focus on cost issues only. Therefore, to gen-
erate sufficient articles from the review, we have defined
“relevant economic studies” as those that have attempt-
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ed to measure costs. Although the measurement of
costs alone is not ideal, such studies can still provide
useful information (but it should be noted that any rec-
ommendation of treatment options should ideally be
based on an assessment of costs and benefits).
To appreciate fully the review and the importance
of adequate reporting, one should have an under-
standing of the underlying principles of costing. To
that end, the next section presents a brief outline of
the costing methodology that should be adopted in
an economic study. This is followed by a description
of the search strategy and the reporting guidelines
used to assess each of the studies identified in the
search. The results of the systematic review and appli-
cation of the guidelines are then presented. A discus-
sion of the main findings and their implications fol-
lows, before we offer some concluding comments.
PRINCIPLES OF COSTING
The central tenet of costing in economic evaluation
is the concept of opportunity cost. As indicated above,
the opportunity cost of using resources in a particular
health care program is equivalent to the benefits that
would have accrued had those resources been utilized
in their next best alternative use. For example, the
opportunity cost of a new angiography suite is the ben-
efit that would have accrued had those resources been
used to improve rehabilitation facilities (assuming the
latter is the next best use of resources). Although
Table I.* Identification, measurement, and valuation of costs
Resource use Measured how? Basis of valuation
HEALTH SERVICES
- staffing time wage rates/salaries 
(eg hours months, years) plus other labor costs
- consumables units/amounts market prices
consumed
- overheads units/amounts wage rates plus other labor 
consumed costs/market prices (allocated)
- capital units/amounts market prices/conversion
consumed costs/official valuer’s estimate
OTHER RELATED SERVICES
- community services as above as above
- ambulance services as above as above
- voluntary services as above imputed values 
for staff costs
CLIENTS AND THEIR FAMILIES
- inputs to treatment hours wages rates plus other
labor costs imputed values
- expenses units/amounts market prices/
consumed actual expenses
*Adapted from Donaldson and Shackley.12
opportunity cost as a concept focuses on benefits for-
gone and is useful for identifying resource use, the prac-
tical application of opportunity cost requires that a dol-
lar value is assigned to the forgone benefit.
A costing exercise can be broken down into three
distinct stages— identification, measurement, and val-
uation. In the identification stage, items to be includ-
ed in a costing exercise are any resources that have an
opportunity cost as a result of being used in the health
care program under consideration. While this may
seem obvious, there is a common misconception that
costs are any negative effect of a health care program.
For example, anxiety is often counted as a cost.
However, anxiety is not a resource that can be used in
some other beneficial activity and therefore does not
have an opportunity cost. Of course, anxiety and
other negative effects on well-being are important
and should not be ignored in a full economic evalua-
tion. Effects on well-being (both positive and nega-
tive) should be dealt with on the benefit side of the
evaluation. Uses of resources (including any saving in
resources) are the concern of costing exercises.
Table I lists the categories of cost that may be
included in a costing exercise. The list is not exhaus-
tive, nor should all categories of cost be included in
every evaluation. Which costs are included will depend
on the perspective of the study, which can range from
that of a single laboratory or hospital to a third-party
payer or society. As an example, if the perspective of
the study is that of a hospital, then costs incurred by
clients and their families should not be included. It is
important to be aware of the perspective when com-
paring costs between studies because different per-
spectives for the same procedure may result in differ-
ent cost estimates and thus alter conclusions.
The costs listed in Table I are commonly referred
to as the direct costs of a health care program. There is
another category of costs known as indirect costs that
are secondary and relate to paid and unpaid productive
activities. Productive activities are those arising from
participation in the labor force and from housework.
Indirect costs arise because treatment could require
confinement to the hospital or one’s home. This can
result in a temporary loss to the community from
reduced productive activity. The danger in including
such costs is that they may have occurred anyway
because of the patient’s illness, and so the actual treat-
ment itself does not add to opportunity costs. Thus, it
is the cost of inputs to treatment that are relevant and
not the cost of the patient’s illness. The identification,
measurement, and valuation of indirect costs can be
quite complex, and opinion is divided about whether,
and how, such costs should be included in an evalua-
tion.18-21 If they are included, they should be report-
ed separately from direct costs.15
With reference to Table I, staff costs generally
constitute the largest proportion of the running costs
of a health care program. Consumables are those items
that are used by (or on behalf of) patients, such as
drugs, or those that have to be replaced on a regular
basis, such as medical supplies. Overheads are costs
shared by more than one program (eg, administra-
tion, lighting, heating). Capital includes such items as
land, buildings, and major equipment. It may be
thought that such items have already been paid for
and therefore should not be included in a costing
exercise. However, if the items have an alternative
beneficial use, then they have an opportunity cost that
should be valued in some way. Even if there is no
obvious alternative use, items may be sold and the
proceeds used in another beneficial activity.
Community, ambulance, and voluntary services
also incur costs of staffing, consumables, overheads,
and capital. It may be thought that voluntary ser-
vices have a zero cost because they are provided free
of charge. However, the use of voluntary services in
one program precludes their use in another pro-
gram and therefore they have an opportunity cost.
Clients and their families may also incur costs
through out-of-pocket expenses or through their
time (which has an opportunity cost).
Having identified the costs to be included, the next
steps are to measure then value resource use. A
detailed description of the various methods of doing
this is beyond the scope of this article (see Drummond
et al1 and Donaldson and Shackley12 for details).
However, some important points can be identified
that merit further discussion here. 
Measuring resource use involves recording the nat-
urally occurring units in which resources are used. For
example, staffing costs are usually measured in units of
time while other items of resource use will be measured
in various other units (eg, grams of drugs). Valuing
resource use is, in may cases, straightforward. In gener-
al, the value of any item of resource use is simply the
quantity of the resource consumed multiplied by its
unit cost (or price). Staff costs, for example, can there-
fore be calculated by multiplying the number of hours
devoted to the program by the hourly wage rate or
salary plus other labor costs. While it may not always be
advisable to accept such monetary figures at face value,
market values are generally accepted as first approxima-
tions to the unit costs of most items within the cate-
gories of staff, consumable, overheads, and capital.
Despite appearing straightforward, there are a
number of points worth noting when measuring and
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valuing costs (all of which relate directly to the critical
assessment guidelines used below). The first is that the
use of hospital charges in costing exercises should be
avoided. Charges do not necessarily reflect actual
resource use and therefore are not to be recommended
(see, for example, Finkler22). What is required is an
explicit statement of the various resources used in the
program. Quite often, only the final dollar value (ie, the
product of the quantity of resource used and the unit
cost) is reported. However, because price and quantity
data may vary between one setting and another, this
value may not be directly applicable to another location
or context. Costings in which the quantity and unit
cost of each item are reported separately (as well as a
product) are more useful because others are allowed to
judge the relevance of the estimates to their own setting
and make any necessary adjustments.
It is also important that the methods used to esti-
mate resource use and unit costs are reported. If meth-
ods of estimation are not reported, others will be unable
to form opinions regarding the validity and reliability of
the estimates, and consequently the validity and gener-
alizability of the results will be called into question.
An obvious, but nevertheless important, point
when measuring and valuing resource use is that
costs should be measured in a base year. That is, all
costs should be adjusted to the price level that per-
tains to a single year, thereby eliminating the effects
of inflation. The choice of year is incidental. What is
important is that it is the same year for all the costs
quoted. That said, it is, of course, crucially important
that whatever year is chosen as the base year must be
reported in the study. If it is not, then the usefulness
of the estimates in terms of comparability and gener-
alizability is significantly diminished because the
effects of inflation cannot be accounted for.
It is inevitable in a costing exercise that there will be
a degree of uncertainty over particular estimates. Quite
often, it is not possible to estimate costs accurately and,
consequently, assumptions may have to be made
regarding the values such costs could take. Where this
happens, it is important to test the sensitivity of the
results or conclusions of a costing exercise to variations
in variables about which there is uncertainty. Such an
exercise is called sensitivity analysis and is an integral
part of any economic evaluation. In some cases,
assumptions about the possible values a variable can
take in a sensitivity analysis are arbitrary. On other occa-
sions, it may be possible to base a sensitivity analysis on
the confidence limits of a statistical estimate of a vari-
able. Whatever method is used, the importance of sen-
sitivity analysis increases in line with the degree of
uncertainty in a study.
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A simple example of sensitivity analysis in an eco-
nomic study of peripheral vascular disease is provided
by Fillinger et al.23 The study compared the actual cost
of performing noninvasive laboratory studies with two
alternative reimbursement systems. On the basis of
their initial calculations, the authors concluded that
actual costs exceeded reimbursement. However, it was
noted that in making the comparison there was uncer-
tainty over the assumption regarding the efficiency
level of the operating laboratory. To allow for this
uncertainty, the authors repeated their calculations for
a range of different efficiency levels and found that
their conclusions were unchanged, thus demonstrating
the robustness of their findings.
METHODS
Search strategy
The aim of the search was to identify articles that
focus on the cost implications of peripheral vascular
surgery. The main databases used were MEDLINE,
EMBASE (Excerpta Medica), Science Citation
Index and Social Science Citation Index (all via the
BIDS service), HEALTHSTAR, DHSS-DATA,
HELMIS (Nuffield Institute for Health, University
of Leeds), and the Cochrane Library. The databases
were searched back to 1986 (it was anticipated that
the return in terms of relevant articles identified
prior to 1986 would be small relative to the research
costs of extending the search period). Relevant cita-
tions from retrieved articles were identified once
these articles had been retrieved and scrutinized.
The keywords used in the search are listed in
Appendix II. 
A number of exclusion criteria were used in the
selection of the articles. An article was rejected if it
conformed with one or more of the following crite-
ria: it was not written in English; it was not pub-
lished in a journal; it was an editorial, a letter, or an
abstract; the procedures in the article were not rele-
vant to peripheral vascular surgery; there was no
original data collection regarding resource use; the
cost data presented were hospital charges or pay-
ments (hospital charges or payments do not neces-
sarily reflect actual resource use).
The abstracts of the articles identified by the
search were read, and those articles that could defi-
nitely be rejected on the basis of the above criteria
were excluded. The remaining articles were obtained
and read. Further application of the exclusion criteria
resulted in the identification of all relevant articles to
be included in the review. Various summary informa-
tion was extracted from the articles before subjecting
them to scrutiny of their reporting quality.
Reporting guidelines
To assess the extent of reporting in the studies
identified in the review, we used the reporting
guidelines put forward by the British Medical
Journal Economic Evaluation Working party.15 It
was decided to use these guidelines in preference to
other available guidelines for reasons that follow.
First, they are directly based on the critical appraisal
guidelines developed by Drummond et al.7 As allud-
ed to above, these critical appraisal guidelines are the
most well known and widely used in health eco-
nomics and have formed the basis of many subse-
quent sets of guidelines developed by others.
Second, unlike some guidelines, the BMJ guidelines
are not pharmaceutical specific. Rather, they have
been developed with the intention of being general-
ly applicable. Finally, they are the least prescriptive of
the available guidelines. This last point is, in our
opinion, particularly important in that there is a dan-
ger that overly prescriptive guidelines can discourage
the development of innovative methods in econom-
ic studies. In drawing up their guidelines, the BMJ
Working Party was aware of this potential problem:
It was not our intention to be unduly prescriptive or
stifle innovative methods; our emphasis is on improving
the clarity of economic evaluations.15
The guidelines are presented under 10 head-
ings and are designed to be applied to full eco-
nomic evaluations in which the costs and conse-
quences of at least two health care interventions
are compared. However, “partial” evaluations,
such as costing studies, are also catered for in that
the relevant sections of the guidelines can be
applied to such studies.
The guidelines specific to costing are as follows:
• Quantities of resources should be reported sep-
arately from the prices (unit costs) of those resources
• Methods for the estimation of both quanti-
ties and prices (unit costs) should be given
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Table II. Study condition, country, year, and study type
Study* Condition Country Year Study type
1 Not specified USA 1993 Survey of vascular laboratories
2 Stroke prevention USA 1997 Retrospective
3 Abdominal aortic aneurysm USA 1991 Retrospective
4 PAOD: critical ischemia UK 1992 Prospective
5 Stroke prevention USA 1997 Modelling
6 PAOD: critical ischemia UK 1994 Retrospective
7 PAOD: general USA 1993 Randomized trial
8 PAOD: critical ischemia Sweden 1996 Retrospective
9 Not specified USA 1993 Prospective
10 Preoperative examination in Sweden 1996 Prospective
aorta, pelvis and lower limbs
11 Stroke prevention UK 1990 Prospective
12 PAOD: critical ischemia UK 1995 Retrospective
13 Chronic venous insufficiency USA 1997 Prospective
14 PAOD: general and UK 1986 Prospective
critical ischemia
15 PAOD: critical ischemia UK 1995 Pro- & Retrospective
16 PAOD: general USA 1996 Prospective
17 Stroke prevention USA 1995 Prospective
18 PAOD: general France 1994 Prospective
19 PAOD: critical ischemia Norway 1996 Prospective
20 PAOD: critical ischemia UK 1997 Prospective
21 PAOD: critical ischemia UK 1997 Prospective
22 Stroke prevention Australia 1995 Retrospective
23 PAOD with diabetes New Zealand 1992 Retrospective
24 PAOD: critical ischemia New Zealand 1994 Retrospective
25 PAOD: general UK 1996 Modelling
26 PAOD: critical ischemia UK 1996 Prospective
and acute ischemia
27 PAOD: general USA 1992 Retrospective
28 PAOD with diabetes New Zealand 1993 Retrospective
29 Stroke prevention Finland 1995 Prospective
30 PAOD: short femoro- Netherlands 1995 Retrospective
popliteal occlusion
PAOD, Peripheral arterial occlusive disease. (There is inevitably a degree of overlap between the PAOD subcategories.)
*See Bibliography.
• The currency and price date should be
recorded and details of any adjustment for inflation,
or currency conversion, given.
In addition to the above criteria, a fourth general
guideline is relevant to costing exercises and relates
to the need to allow for uncertainty in cost estimates
by carrying out a sensitivity analysis. The BMJ
Working Party guideline on sensitivity analysis states:
• When a sensitivity analysis is performed
details should be given of the approach used—for
example, multivariate, univariate, threshold analy-
sis—and justification given for the for the choice
of variables for sensitivity analysis and the ranges
over which they are varied.15
The above four guidelines were applied to the
studies included in the review with a view toward
assessing their reporting quality.
RESULTS
After the application of the exclusion criteria to
the articles identified in the literature search, 30 arti-
cles remained for inclusion in the review (see the
Bibliography for a list of these articles). 
For each of the 30 studies, Table II summarizes
the study condition, the country in which the study
took place, the year of publication, and the type of
study on which the costing exercises were based.
Only one of the 30 studies was published before
1990, and more than half (17 studies) were pub-
lished in the last 21⁄2 years of the search period. This
pattern is indicative of the relatively recent growth in
economic studies and vindicates our decision to not
extend the search period back before 1986.
The 30 studies were undertaken in nine different
countries, with the majority taking place in the
United Kingdom and the United States. Interestingly,
nine of the 10 studies from the United Kingdom
focused on peripheral arterial occlusive disease, with
eight of these focusing specifically on limb ischemia.
This contrasts with the studies from the United
States, which covered a wider range of conditions. 
With respect to the costing exercises, 14 involved
prospective data collection, 11 involved retrospective
data collection, and one involved a combination of
both. Perhaps surprisingly, only one study involved a
randomized trial. Of the remaining three studies, two
were modeling exercises and the other involved a
postal survey of vascular laboratories. With respect to
the modeling studies, it might be thought that apply-
ing the costing guidelines to them is inappropriate,
particularly because the BMJ guidelines contain a sec-
tion specific to modeling exercises. However, both
studies include cost estimates in their models, and as
such we would argue that the application of the cost-
ing guidelines is therefore merited.
The procedures costed in the studies are present-
ed in Table III. Reconstruction, bypass, and revas-
cularization were the most commonly costed proce-
dures (12 studies), followed by amputation (11
studies). The other procedures that were costed in
more than one study are duplex/Doppler ultra-
sound (seven studies), angioplasty (five studies),
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Table III. Procedure costed by study
Procedure costed Study*
Investigations:
Duplex/Doppler ultrasound (A) 1, 2, 9, 10, 11, 17, 29
Angiography (B) 10, 17, 29
CT scan (C) 29
Surgical procedures:
Reconstruction/by-pass/revascularization (D) 4, 6, 8, 12, 14, 15, 16, 19, 20, 21, 25, 26
Thromboendarterectomy (E) 30
Amputation (F) 4, 6, 8, 12, 15, 19, 20, 21, 24, 25, 26
Carotid endarterectomy (G) 2, 5, 17, 22
Abdominal aortic aneurysm repair (H) 3
Subfascial endoscopic perforator surgery (I) 13
Endovascular procedures:
Angioplasty (J) 8, 14, 15, 25, 26, 30
Drug treatments:
Iloprost (K) 24
Pentoxyfilline (L) 27
Cefamandole and cefazolin (M) 7
Other:
Treatment of diabetic peripheral arterial 23, 28
occlusive disease (N)
Not specified (O) 18
*See Bibliography.
carotid endarterectomy (four studies), angiography
(three studies), and the treatment of diabetic periph-
eral arterial occlusive disease (two studies).
We have chosen not to report the actual cost esti-
mates from the studies. The reason for this is that
the cost estimates alone are effectively meaningless
without knowing the details of how they were cal-
culated. Numerous factors can affect cost estimates,
such as whether the costs are total, average, or mar-
ginal; the perspective of the study; whether
allowance has been made for differential timing of
costs through the application of discounting; and
other key assumptions. Single estimates of cost
should not be taken at face value without first assess-
ing the methods used to produce the estimates.
The results of applying the BMJ reporting guide-
lines to the 30 studies are summarized in Table IV.
(It should be noted that in the table, the guideline
that refers to the methods for the estimation of
quantities of resources and their prices has been split
into two.) With respect to costing guidelines, the
studies perform best in terms of reporting the meth-
ods of estimating prices and quantities of resources.
Twenty-one studies provided information on prices,
and 19 reported quantity of resources information.
When it comes to reporting quantities of resources
separately from price, however, the studies perform
less well with only eight of them conforming to this
guideline. The studies can also be criticized for not
stating the year in which the prices are given, with
17 omitting this information.
The studies perform quite well in terms of the
sensitivity analysis guideline in the sense that when a
sensitivity analysis was performed, details were
reported in all but one case. However, if the group
of studies were judged in terms of the number
undertaking a sensitivity analysis, then they can be
said to perform poorly because only five of them did
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Table IV. Assessment of reporting standards
Quantities of Methods of Methods of Sensitivity
resources reported estimating estimating Year of prices analysis Procedure 
Study separately from price quantities given prices given given/currency performed costed*
1 Yes Yes Yes No US$ No A
2 No No No No US$ No A,G
3 No No Yes No US$ No H
4 No Yes Yes 1989 US$ No D,F
5 No Yes Yes 1996 US$ Yes G
6 No Yes No 1989 UK£ No† D,F
7 Yes Yes Yes No US$ No M
8 Yes No Yes 1996 US$ No D,F,J
9 Yes Yes Yes No US$ Yes A
10 No No No 1993 SEK No A,B
11 No Yes Yes No UK£ No A
12 No No No No UK£ No D,F
13 No No No No US$ No I
14 No Yes Yes 1984 UK£ No‡ D,J
15 Yes Yes No No UK£ No§ D,F,J
16 No Yes Yes No US$ No D
17 No No Yes 1993 US$ Yes A,B,G
18 No Yes No No US$ No O
19 No No No No UK£ No D,F
20 No Yes Yes 1994/5 UK£ No D,F
21 No Yes No No UK£ No D,F
22 Yes Yes Yes No Aus$ No G
23 No Yes Yes 1989 NZ$ No N
24 No Yes Yes No NZ$ No F,K
25 No Yes Yes 1993/4 UK£ Yes D,F,J
26 Yes No Yes No UK£ No¶ D,F,J
27 No Yes Yes 1989 US$ No L
28 Yes No Yes No NZ$ No N
29 No No Yes 1994 US$ No A,B,C
30 No Yes Yes 1990 DGL Yes# E,J
* See Table III for classification of conditions. On one cost only.
† Range given for amputation costs. ¶Interquartile ranges given for some costs.
‡ Range given for length of stay. #Details not given.
§ Range given for some costs. US$, US dollars; UK£, UK sterling, SEK, Swedish krona; Aus$, Australian
dollars; NZ$, New Zealand dollars; DGL, Dutch guilders.
so. Of course, whether a study undertakes a sensitiv-
ity analysis is not covered by the reporting guide-
lines. However, in view of the importance of sensi-
tivity analysis, we feel the dearth of such an exercise
among the studies is worthy of note.
DISCUSSION
The raison d’être of economic evaluation is to aid
policy decisions regarding the allocation of scarce health
care resources. In formulating such decisions, it is clear-
ly desirable for decision makers to be able to distinguish
between “good” evidence and “bad” evidence. As
Mason and Drummond24 note: “Users of economic
evaluations need to be sure that the methodological
quality of published studies is satisfactory.”
This is particularly important because the num-
ber of economic evaluations appearing in the litera-
ture continues to increase at such a rapid rate. As
indicated above, to aid quality assessment, a number
of critical appraisal guidelines exist. Most notable
among these are the guidelines produced by
Drummond et al7 that are reproduced in Appendix
I. It is evident from an inspection of these guidelines
that in order to apply them fully to an economic
evaluation, a minimum standard of reporting is
required. Hence the argument put forward in this
article that adequate reporting in economic studies
is a prerequisite (or necessary) condition for judging
the quality of such studies.
Inability to apply critical appraisal criteria
because of inadequate reporting can significantly
diminish the usefulness and potential impact of an
economic study. This can be simply illustrated by
considering two studies in the review (Myhre et al,
study 19 in the Bibliography, and Singh et al, study
26 in the Bibliography) that calculated costs for pri-
mary amputation caused by critical limb ischemia.
Both studies were published in 1996 and both quot-
ed costs in UK Sterling (although it should be noted
that neither study explicitly stated the base year for
the price data). The estimated costs of amputation
were £9,700 (Myhre et al) and £10,162 (Singh et
al). While these estimates are very similar, closer
reading of the articles reveals that Singh et al adopt-
ed a broader perspective than Myhre et al and con-
sequently included a wider range of costs (eg, occu-
pational therapy, physiotherapy, disablement services
[including prostheses], convalescence, home adapta-
tion, home care, district nursing, transportation, and
outpatient visits. Moreover, Singh et al reported
medians and Myhre et al appear to have reported
means. In view of these differences, one might
expect the cost estimates to be further apart than
reported. In these circumstances, an assessment of
the costing methodology of both studies would
seem to be particularly appropriate. Application of
questions 5 and 6 from the Drummond et al7 criti-
cal appraisal guidelines reveals a difference between
the two studies. With Singh et al, the level of report-
ing is such that it is possible to assess whether costs
were measured accurately in appropriate physical
units and if they were valued credibly (and in both
cases, the answer is a qualified yes). Such an assess-
ment is not possible with Myhre et al, however,
because the extent of the reporting is too brief. In
these circumstances, even though there is no evi-
dence to suggest that the cost estimate by Myhre et
al is wrong, potential users of these data would have
to ascribe relatively more weight to the cost estimate
from Singh et al simply because its methodology is
more transparent.
Even if it were somehow known that an econom-
ic study (eg, Myhre et al) was methodologically
sound, inadequate reporting still presents a problem
in that it hinders the ability of individuals to judge
the applicability of a study’s results and methods to
their own (potentially different) set of circumstances
or conditions. For example, Myhre et al and Singh et
al both include personnel costs in their overall cost
estimates, yet neither provides a breakdown of the
different staff involved. Given that staff profiles may
differ between centers, and that, as stated above, staff
costs generally constitute the largest proportion of
the running costs of a health care program, such
information is important when assessing the applica-
bility of a cost estimate to one’s own setting. 
Having applied the BMJ reporting guidelines to
the vascular costing studies identified in the review,
one is tempted to criticize the studies for reporting
deficiencies. However, it would be unfair to do so
without first comparing them to costing studies in
other clinical areas. Unfortunately, we are unable to do
this because we do not know of any other studies that
have applied reporting guidelines in the way we have
in this article. That said, some indication of the extent
of economic reporting in other area can be gleaned
from Mason and Drummond13,24 and Balas et al.25
Mason and Drummond13,24 comment on the
results of a critical appraisal of 147 economic evalua-
tions contained on a register of cost-effectiveness
studies held by the Department of Health in
England. While the focus of the appraisal was not
reporting standards, some reference is made to
reporting. For instance, they indicate that they found
considerable variation in the basic standard of report-
ing among the 147 studies. They specifically mention
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that the year to which the cost data relate was
ambiguous in around 25% of the studies. They also
state that it was impossible to assess the quality of
many of the studies because of inadequate reporting
and recommend that, in the future, economic studies
should conform to a minimum reporting standard.
Balas et al27 reviewed the medical literature with
the aim of identifying and critically appraising clini-
cal trials containing economic analysis. As with
Mason and Drummond,13,24 their focus was not
reporting standards. However, they did find suffi-
cient deficiencies in reporting to state that the limi-
tations they found in the studies they reviewed
should act as a warning to practitioners and admin-
istrators who routinely make recommendations and
inferences based on incomplete information.
It would seem from the above (admittedly limit-
ed) evidence that reporting inadequacies is a poten-
tial problem in not just peripheral vascular disease,
but also many other clinical areas. Although this is a
cause for concern, it should be set against the fact
that it is only relatively recently that reporting guide-
lines have been published. What would be more of a
concern would be if this study were repeated 10
years hence and no improvement in reporting
found. It is to be hoped this will not be the case.
We are grateful to Andrew Booth for help in carrying
out the systematic review and John Brazier for helpful
comments.
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APPENDIX I
The Drummond et al7 critical appraisal guidelines
for economic evaluations.*
1. Was a well-defined question posed in an 
answerable form?
2. Was a comprehensive description of compet-
ing alternatives given (ie, can you tell who did
what to whom, where, and how often)?
3. Was there evidence that the programme’s
effectiveness had been established?
4. Were all important relevant costs and conse-
quences for each alternative identified?
5. Were costs and consequences measured accu-
rately in appropriate physical units (eg, hours
of nursing time, number of physician visits,
days lost from work, or years of life gained)
prior to valuation?
6. Were costs and consequences valued credibly?
7. Were costs and consequences adjusted for dif-
ferential timing?
8. Was an incremental analysis of costs and con-
sequences of alternatives performed?
9. Was a sensitivity analysis performed?
10. Did the presentation and discussion of the
results of the study include all issues of con-
cern to users?
*Each of the 10 questions has a number of subques-
tions that have not been reported here.
APPENDIX II
The keywords used in the searches of the data-
bases were as follows:
1. “PERIPHERAL-VASCULAR
-DISEASES”/ all subheadings 
2. LA = “ENGLISH” 
3. #1 and (LA = “ENGLISH”) 
4. ECONOMICS 
5. COSTS-AND-COST-ANALYSIS* 
6. #4 or #5 
7. #3 and #6 
8. AORTIC-ANEURYSM* 
9. #6 and #8 
10. #7 or #9 
11. “VASCULAR-SURGERY-
ECONOMICS” 
12. #10 or #11 
13. “AORTIC-RUPTURE” 
14. #6 and #13 
15. #12 or #14 
16. J-VASC-SURG 
17. #6 and #16 
18. #15 or #17 
19. ISCHEMIA 
20. “ISCHEMIA” IN MJME 
21. #6 and #20 
22. #18 or #21 
23. LA = “ENGLISH” 
24. #22 and (LA = “ENGLISH”) 
25. “ARTERIAL-OCCLUSIVE-DISEASES-
ECONOMICS” 
26. “CAROTID-ARTERY-DISEASES-
ECONOMICS” 
27. “INTERMITTENT-CLAUDICATION
-ECONOMICS” 
28. “ENDARTERECTOMY-ECONOMICS” 
29. #24 or #25 or #26 or #27 or #28 
30. PERIPHERAL 
31. VASCULAR 
32. PERIPHERAL 
33. ARTERIAL 
34. (PERIPHERAL VASCULAR) OR 
(PERIPHERAL ARTERIAL) 
35. #6 and #34 
36. #29 or #35 
37. LA = “ENGLISH” 
38. #36 and (LA = “ENGLISH”) 
39. “LEG-BLOOD-SUPPLY” 
40. “SEMIN-VASC-SURG” 
41. “EUR-J-VASC-ENDOVASC-SURG” 
42. “EUR-J-VASC-SURG” 
43. #39 or #40 or #41 or #42 
44. #6 and #43 
45. #38 or #44 
46. LA = “ENGLISH” 
47. #45 and (LA = “ENGLISH”) 
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